• Explore /
  • Poster
  • / Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC).

Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC).

Abstract Poster

Authors

Thomas Hutson

Thomas E. Hutson

Texas Oncology–Baylor Charles A. Sammons Cancer Center, Dallas, TX

Thomas E. Hutson , Dmitry Nosov , Timothy Eisen , Oleg N. Lipatov , Piotr Tomczak , Anna Alyasova , Mihai Harza , Mikhail Kogan , Boris Y. Alexseev , Cezary Szczylik , Andrew Louis Strahs , Brooke Esteves , Anna Berkenblit , Robert John Motzer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Renal Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT01030783

Citation

J Clin Oncol 31, 2013 (suppl 6; abstr 354)

DOI

10.1200/jco.2013.31.6_suppl.354

Abstract #

354

Poster Bd #

B7

Abstract Disclosures

Similar Posters

First Author: Thomas Hutson

First Author: Sumanta K. Pal

First Author: Sumanta K. Pal

First Author: Brian I. Rini